|
A
Bittersweet Reminder In Neon Lights
Monday 18 December 2006: A striking
neon artwork depicting proteins related
to deadly diseases will mesmerize passers-by
in the centre of London, and act as a bittersweet
reminder of the devastation of serious medical
conditions.
215 Euston Road is the home of the UK's
largest independent medical charity, the
Wellcome Trust, and its front windows are
a unique opportunity for the public to learn
more about the science and issues surrounding
health and wellbeing today. Approximately
5,000 people pass-by the Wellcome Trust
on a daily basis.
Proteins play a key part in how our bodies
interact with disease. The Structural Genomics
Consortium, which the Wellcome Trust part
funds, has had a crucial role in identifying
the structure of some important proteins
related to human disease, including cancer,
HIV, obesity and malaria. Understanding
the structures offers potential targets
for novel drugs to treat these conditions.
London designers Graphic Thought Facility
have constructed a colourful and thought
provoking display depicting a number of
these proteins in bright neon signs that
will attract the attention of busy onlookers.
Clare Matterson, Director, Medicine,
Society and History, The Wellcome Trust,
comments: "Graphic Thought Facility's
display relates to biomedical issues of
global significance where Wellcome Trust-funded
research is making a difference. Clearly
the new display marks the beginning of an
exciting period of development on Euston
Road, as we prepare for the launch of our
first public venue Wellcome Collection,
in the summer of next year."
Paul Neale, Director, Graphic Thought
Facility, said: "It is the first
time we have experimented with neon on this
scale, and the results are impressive. We
have worked closely with the Wellcome Trust
to understand the nature of these proteins.
It's difficult to comprehend how something
so beautiful can represent such serious
conditions."
The new window display will be unveiled
to the public on Monday 18 December 2006.
Graphic Thought Facility's design is the
third commission for the Wellcome Trust's
Gibbs Building. The first was a series developed
by Doshi Levien for the opening of the building
in August 2004, and the second was by Glasgow
designers Timorous Beasties, inspired by
the Wellcome Trust's work on the human genome
and malaria.
END
Notes To Editors
Media enquiries
Mike Findlay, Wellcome Trust
E m.findlay@wellcome.ac.uk
T +44 (0)20 7611 8612
The Wellcome Trust (www.wellcome.ac.uk)
The Wellcome Trust is the largest independent
medical research charity in the UK and the
second largest in the world. It funds innovative
biomedical research, in the UK and internationally,
spending around £500 million each year
to support the brightest scientists with the
best ideas. The Wellcome Trust is committed
to public debate about biomedical research
and its impact on health and wellbeing.
Graphic Thought Facility (http://www.graphicthoughtfacility.com/)
Graphic Thought Facility is a London-based
graphic design consultancy. Established
as a partnership in 1990 and as a limited
company in 1997, Graphic Thought Facility
work on national and international projects.
Significant projects include brand-identity
and signage for Frieze Art Fair (2002-6);
brand-identity for the Design Museum (2002)
and exhibition design their Designer of
the Year (2002-6); re-branding, packaging,
marketing and press material for Habitat
(1996-2002); store graphics and signage
for Marks & Spencer (2004-6); catalogue
designs for the Saatchi Collection (2002)
and The Carnegie Museum of Arts' 54th International
(2004).
The Structural Genomics Consortium (SGC)
http://www.sgc.utoronto.ca/
SGC is a not-for-profit organization that
aims to determine the three dimensional
structures of proteins of medical relevance,
and place them in the public domain without
restriction. The SGC operates out of the
Universities of Oxford and Toronto and Karolinska
Institutet, Stockholm. The SGC works on
structures of proteins from its Target List
of ~2,000 proteins, which comprises human
proteins associated with diseases such as
cancer, diabetes, inflammation, and genetic
diseases, as well as proteins from human
parasites such as those that cause malaria.
Wellcome Collection (www.wellcomecollection.org.uk)
The Wellcome Trust's former headquarters,
The Wellcome Building on London's Euston
Road, has been redesigned by Hopkins Architects
to become a new £30m public venue
opening in summer 2007. Free to all, Wellcome
Collection will explore the connections
between medicine, life and art in the past,
present and future. The building will comprise
three galleries, a public events space,
the Wellcome Library, a café, a bookshop,
conference facilities and a members' club.
The five neon signs are based on the
following protein structures:
Leptin and Obesity
Protein Database number 1AX8
Leptin is the protein that regulates how
people's bodies store fat. It inhibits eating,
by making you feel full instead of hungry.
It also makes you burn off calories. Leptin
was originally discovered by studying mutant
mice that didn't know when to stop eating
and so became huge. In 1994 researchers
discovered that the reason these mice ate
so much was that they couldn't produce proper
leptin.
In rare cases, people can't make leptin
properly and become obese. Leptin treatment
can help them lose weight. For most of the
population however there appears to be no
correlation between obesity and the different
forms of the gene that produces leptin.
Developing Antibiotics
Plasmodium yoelii holo-(Acyl-carrier protein)
synthase
SGC Database number 2BDD
Fatty acids are used by all organisms.
They make up the membranes that hold cells
and their contents together and store energy.
This protein is part of the pathway used
to make fatty acids by Plasmodium yoelii,
one of the protozoans that cause malaria
in mice. Bacteria use a very similar protein
so that they can grow and divide to produce
new bacteria. Humans use a different pathway
which doesn't include a protein like this
to make fatty acids. By designing drugs
to target such proteins, which bacteria
and malaria parasites use and humans don't,
it could be possible to develop antimalarial
treatments and/or antibiotics that kill
bacteria without harming their human hosts.
Fighting Cancer
Human WD repeat domain protein 5 (WDR5)
SGC Database number 2GNQ
WDR5 is one of the huge number of proteins
in any cell whose job it is to switch genes
on and off at the right times. The DNA in
which our genes are encoded is wrapped around
proteins called histones, and whenever a
cell wants to turn on a gene it has to first
unwrap them. WDR5 is one of the proteins
that aid this unwrapping. In cancer, cells
divide because the wrong genes are switched
on or off. Since many of the genes that
WDR5 helps to control are involved in shaping
an animal as it grows, turning them on in
an adult can mean new disorganised growth
which can form a tumour.
Researching Drugs to Treat Malaria
PPWD1 from the malaria parasite Plasmodium
falciparum
SGC Database number 2FU0
PPWD1 is a protein that helps other proteins
fold into the correct shape as they are
made. The human version is involved in cell
division and is part of the immune system.
Some drugs that are used to shut down the
immune system - following transplant surgery,
for example, or in patients with inflammation
- act by forming a complex with PPWD1. This
PPWD1 is taken from one of the protozoans
that causes malaria in humans, called Plasmodium
falciparum. Because this protein is so similar
to the human version, drugs originally designed
for use in humans target this protein in
the Plasmodium and stop it working, thus
potentially preventing the development of
malaria.
Studying HIV
SGC Database number 2C46
Like any virus, HIV (which causes AIDS)
takes over the machinery of a host cell
in order to reproduce. One of the human
proteins that it hijacks is Human Capping
Enzyme 1. Normally this protein is involved
in the process of using the instructions
in human DNA to build other proteins. These
instructions are copied into a portable
form, called messenger RNA, and Human Capping
Enzyme 1 modifies the messenger RNA, adding
a chemical 'cap'. The cap signals to the
cell that it needs to make a protein based
on this RNA. HIV uses Human Capping Enzyme
1 to attach cap signals to its own RNA,
tricking the human cell into making HIV
proteins and helping the virus reproduce.
END TO ALL
|